CA2608163A1 - Compositions d'hydralazine et procedes associes - Google Patents

Compositions d'hydralazine et procedes associes Download PDF

Info

Publication number
CA2608163A1
CA2608163A1 CA002608163A CA2608163A CA2608163A1 CA 2608163 A1 CA2608163 A1 CA 2608163A1 CA 002608163 A CA002608163 A CA 002608163A CA 2608163 A CA2608163 A CA 2608163A CA 2608163 A1 CA2608163 A1 CA 2608163A1
Authority
CA
Canada
Prior art keywords
macular degeneration
salt
subject
composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002608163A
Other languages
English (en)
Other versions
CA2608163C (fr
Inventor
George C. Chiou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
The Texas A & M University System
George C. Chiou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Texas A & M University System, George C. Chiou filed Critical The Texas A & M University System
Publication of CA2608163A1 publication Critical patent/CA2608163A1/fr
Application granted granted Critical
Publication of CA2608163C publication Critical patent/CA2608163C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2608163A 2005-05-12 2006-05-04 Compositions d'hydralazine et procedes associes Expired - Fee Related CA2608163C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68099805P 2005-05-12 2005-05-12
US60/680,998 2005-05-12
US77642606P 2006-02-24 2006-02-24
US60/776,426 2006-02-24
US11/416,773 US8088773B2 (en) 2005-05-12 2006-05-03 Therapeutic compositions and methods
US11/416,773 2006-05-03
PCT/US2006/017329 WO2006124324A1 (fr) 2005-05-12 2006-05-04 Compositions therapeutiques et methodes associees

Publications (2)

Publication Number Publication Date
CA2608163A1 true CA2608163A1 (fr) 2006-11-23
CA2608163C CA2608163C (fr) 2011-10-25

Family

ID=37431545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2608163A Expired - Fee Related CA2608163C (fr) 2005-05-12 2006-05-04 Compositions d'hydralazine et procedes associes

Country Status (10)

Country Link
US (5) US8088773B2 (fr)
EP (3) EP1885371A4 (fr)
JP (2) JP5335419B2 (fr)
AU (1) AU2006247892B2 (fr)
CA (1) CA2608163C (fr)
DE (1) DE202006020318U1 (fr)
ES (1) ES2598277T3 (fr)
HK (1) HK1177419A1 (fr)
PL (1) PL2508182T3 (fr)
WO (1) WO2006124324A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120828A1 (fr) * 2006-04-14 2007-10-25 Novartis Ag Utilisation d'anticorps anti-il-1 pour le traitement de troubles ophtalmiques
US7736860B2 (en) * 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
EP3318264A1 (fr) * 2009-08-24 2018-05-09 Stealth Peptides International, Inc. Procédés et compositions de prévention ou de traitement d'affections ophtalmiques
AU2013274582A1 (en) 2012-06-11 2015-01-22 Macuclear, Inc. Therapeutic formulation and methods of treatment
CA2884644A1 (fr) * 2012-09-13 2014-03-20 Cba Pharma, Inc. Formulations pharmaceutiques de tetrandrine et procede associe
EP3026054B1 (fr) 2013-07-23 2019-03-06 Eisai R&D Management Co., Ltd. Composé cyclique hétérocondensé
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
US20190177258A1 (en) 2017-12-11 2019-06-13 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
CA3103436A1 (fr) * 2018-06-11 2019-12-19 The Regents Of The University Of California Demethylation pour traiter une maladie oculaire
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
CN114276251B (zh) * 2021-12-07 2022-12-16 武汉大学 一种合成硝基(杂)芳烃的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) * 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
FI873428A (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
IT1201151B (it) 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5194434A (en) * 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422166A (en) * 1993-02-12 1995-06-06 Wangner Systems Corporation Abrasion resisting edge for a forming fabric
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
JP3541389B2 (ja) 1996-04-26 2004-07-07 藤沢薬品工業株式会社 ジヒドロピリジン化合物を含有する眼組織末梢循環改善剤
US6066675A (en) * 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
JP4828670B2 (ja) 1996-10-28 2011-11-30 千寿製薬株式会社 眼循環障害改善剤
CA2323749A1 (fr) 1998-03-06 1999-09-10 William E. Sponsel Traitement de troubles maculaires et composition appropriee
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
AU3395800A (en) * 1999-03-05 2000-09-21 University Of Iowa Research Foundation, The Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
EP2241328A1 (fr) * 2000-05-12 2010-10-20 Immunex Corporation Inhibiteurs d'interleukine 1 dans le traitement de maladies
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
CA2504334A1 (fr) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identification de composes therapeutiques en fonction de leur proprietes physico-chimiques
JP2004250347A (ja) * 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20080300292A1 (en) * 2004-11-08 2008-12-04 Nitromed, Inc Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders

Also Published As

Publication number Publication date
CA2608163C (fr) 2011-10-25
JP2008540528A (ja) 2008-11-20
US20130059841A1 (en) 2013-03-07
EP1885371A4 (fr) 2010-04-07
JP2012229257A (ja) 2012-11-22
EP1885371A1 (fr) 2008-02-13
ES2598277T3 (es) 2017-01-26
US8088773B2 (en) 2012-01-03
EP2508182A1 (fr) 2012-10-10
US20120196868A1 (en) 2012-08-02
WO2006124324A1 (fr) 2006-11-23
US20120115959A1 (en) 2012-05-10
US20060276458A1 (en) 2006-12-07
EP2508183B1 (fr) 2014-07-09
EP2508183A1 (fr) 2012-10-10
EP2508182B1 (fr) 2016-07-06
US8318741B2 (en) 2012-11-27
JP5335419B2 (ja) 2013-11-06
JP5643263B2 (ja) 2014-12-17
AU2006247892B2 (en) 2010-04-22
AU2006247892A1 (en) 2006-11-23
US20120071485A1 (en) 2012-03-22
HK1177419A1 (en) 2013-08-23
PL2508182T3 (pl) 2017-05-31
DE202006020318U1 (de) 2008-07-31

Similar Documents

Publication Publication Date Title
CA2608163A1 (fr) Compositions d'hydralazine et procedes associes
JP2008540528A5 (fr)
CN102548548B (zh) 用于医学和兽医学的眼科药物组合物
US10022419B2 (en) Methods for treating spinal cord injury
US20130137642A1 (en) Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2007061661A4 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
RU2011103741A (ru) Композиции и способы лечения заболевания сетчатки
US7105512B2 (en) Ophthalmic aqueous pharmaceutical preparation
CA2569691A1 (fr) Methodes et compositions pour traitement de manifestations ophtalmiques au moyen de derives de retinyl
Assadi et al. Impact of Ramadan fasting on intraocular pressure, visual acuity and refractive errors
CN102365093A (zh) 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途
EA201300314A8 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
ZA200510344B (en) Coumarin derivatives for the treatment of ophthalmic disorders
JP2020520949A5 (fr)
JP2009536193A (ja) 予防若しくは治療の形態で投与されるα−ＭＳＨを用いた、改善の余地のある多様な病理学的過程に関する治療におけるニコチン、そのアナログ、その前駆体またはその誘導体の使用
JP2018525447A5 (fr)
US20070299119A1 (en) Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy
CN105142670A (zh) 用于治疗眼部炎性疾病的滴眼剂组合物及其制备方法
PT2692345T (pt) Composição farmacêutica para prevenir ou tratar a degeneração macular
ES2860767T3 (es) Mirabegrón para el tratamiento de enfermedades retinianas
RU2010141560A (ru) Лечение офтальмологических заболеваний
JP2006306757A (ja) 角膜疾患治療剤
CN1836667B (zh) 滴眼剂
JP5560588B2 (ja) 眼科用剤
RU2020111560A (ru) Офтальмологические фармацевтические композиции

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190506